To page body
university of tampere: faculty of medicine and life sciences: research: research groups:
Faculty of Medicine and Life SciencesUniversity of TampereFaculty of Medicine and Life Sciences

Surgery

Professor (Urology):
Teuvo Tammela
tel. +358 (0)40 190 1489
teuvo.tammela@uta.fi

Professor (Surgery, especially Orthopaedics and Traumatology, Seinäjoki):
Harri Pihlajamäki
harri.pihlajamaki@epshp.fi

Professor (Cardiac Surgery):
Jari Laurikka
tel. +358 (0)3 3116 7669
jari.laurikka@sydankeskus.fi

Associate professor (Blood Vessel Surgery):
Niku Oksala
niku.oksala@uta.fi

Clinical teachers:
Heidi Haapasalo (Orthopaedics and Traumatology), e-mail: heidi.haapasalo@uta.fi
Margit Karelson (Arm Surgery), e-mail: margit.karelson@uta.fi
Kirsi Lehto (Gastroenterology), e-mail: kirsi.m.lehto@uta.fi
Teemu Murtola (Urology), e-mail: teemu.murtola@uta.fi
Timo Halonen (Plastic Surgery), Seinäjoki, e-mail: timo.halonen@epshp.fi


Laboratory of Regenerative Medicine >>

Surgery (Cardiac Surgery) >>

Urology >>


Recent publications:

Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A
Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
Prostate Cancer Prostatic Dis ;2018
PMID

Sipeky C, Gao P, Zhang Q, Wang L, Ettala O, Talala K, Tammela TL, Auvinen A, Wiklund F, Wei GH, Schleutker J
CIP2A predispose to aggressive prostate cancer.
Clin Cancer Res ;2018
PMID

Murtola TJ, Syvälä H, Tolonen T, Helminen M, Riikonen J, Koskimäki J, Pakarainen T, Kaipia A, Isotalo T, Kujala P, Tammela TLJ
Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.
Eur Urol ;2018
PMID

Kaapu KJ, Rantaniemi L, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ
Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.
Sci Rep ;8(1)10308, 2018
PMID

Mäkelä VJ, Kotsar A, Tammela TLJ, Murtola TJ
Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
J Urol ;200(4)743-748, 2018
PMID

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ
Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
Prostate Cancer Prostatic Dis ;21(3)373-378, 2018
PMID

Tolonen TT, Riikonen J, Tammela TLJ, Koivusalo L, Haapasalo H, Kujala P, Kaipia A
Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease.
Ann Diagn Pathol ;2018
PMID

Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TL, Auvinen A
Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Int J Urol ;25(3)270-276, 2018
PMID

Kallio HML, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, Tammela TL, Nykter M, Isaacs WB, Lilja HG, Bova GS, Visakorpi T
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Br J Cancer ;2018
PMID

FitzGerald LM, Zhao S, Leonardson A, Geybels MS, Kolb S, Lin DW, Wright JL, Eeles R, Kote-Jarai Z, Govindasami K, Giles GG, Southey MC, Schleutker J, Tammela TL, Sipeky C, Penney KL, Stampfer MJ, Gronberg H, Wiklund F, Stattin P, Hugosson J, Karyadi DM, Ostrander EA, Feng Z, Stanford JL
Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.
Prostate Cancer Prostatic Dis ;21(2)228-237, 2018
PMID

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS
Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues.
Am J Surg Pathol ;42(1)103-115, 2018
PMID

Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A
Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Br J Cancer ;118(9)1248-1254, 2018
PMID

Booth N, Rissanen P, Tammela TLJ, Taari K, Talala K, Auvinen A
Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.
Eur J Cancer ;2018
PMID

Lehto US, Aromaa A, Tammela TL
Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment.
Eur J Cancer Care (Engl) ;2018
PMID

Kivinummi K, Urbanucci A, Leinonen K, Tammela TLJ, Annala M, Isaacs WB, Bova GS, Nykter M, Visakorpi T
The expression of AURKA is androgen regulated in castration-resistant prostate cancer.
Sci Rep ;7(1)17978, 2017
PMID

Eskelinen TJ, Kotsar A, Tammela TLJ, Murtola TJ
Components of metabolic syndrome and prognosis of renal cell cancer.
Scand J Urol ;51(6)435-441, 2017
PMID

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Eur Urol Focus ;3(6)606-614, 2017
PMID

Tammela TL, Häggman M, Ladjevardi S, Taari K, Isotalo T, Lennernäs H, Weis J, von Below C, Wassberg C, Lennernäs B, Tolf A, Axén N, Gölander CG, Ahlström H
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
J Urol ;198(6)1333-1339, 2017
PMID

Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
Eur Urol Focus ;2017
PMID

Kallio J, Hämäläinen M, Luukkaala T, Moilanen E, Tammela TL, Kellokumpu-Lehtinen PL
Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.
Urol Oncol ;35(9)544.e25-544.e31, 2017
PMID

Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A
Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
BMC Cancer ;17(1)585, 2017
PMID

Na R, Helfand BT, Chen H, Conran CA, Crawford SE, Hayward SW, Tammela TLJ, Hoffman-Bolton J, Zheng SL, Walsh PC, Schleutker J, Platz EA, Isaacs WB, Xu J
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
Prostate ;77(11)1213-1220, 2017
PMID

Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A
Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
J Urol ;198(2)305-309, 2017
PMID

Saarimäki L, Hugosson J, Tammela TL, Carlsson S, Talala K, Auvinen A
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Eur Urol Focus ;2017
PMID

Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ, Auvinen A
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
J Urol ;198(1)50-57, 2017
PMID

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, Rinta-Kiikka I, Lehtimäki T, Oksala N, Pettersson K, Tammela TL
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Eur J Epidemiol ;32(6)521-527, 2017
PMID

Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
Cell Rep ;19(10)2045-2059, 2017
PMID

Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ
The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia.
Prostate ;77(9)1029-1035, 2017
PMID

Murtola TJ, Peltomaa AI, Talala K, Määttänen L, Taari K, Tammela TLJ, Auvinen A
Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
Eur Urol Focus ;3(2-3)212-220, 2017
PMID

Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman UH, Tammela TLJ, Auvinen A
Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
Eur Urol Focus ;2017
PMID

Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Scand J Urol ;51(1)5-12, 2017
PMID

Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.
Eur Urol Focus ;2017
PMID

Nevalainen J, Stenman UH, Tammela TL, Roobol M, Carlsson S, Talala K, Schröder FH, Auvinen A
What explains the differences between centres in the European screening trial? A simulation study.
Cancer Epidemiol ;2017
PMID

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Eur Urol ;71(2)151-154, 2017
PMID

 
Maintained by: med.info@uta.fi
Last update: 4.1.2017 15.15 Muokkaa

University of Tampere
+358 3 355 111
registry@uta.fi


FINEEC Audited HR Excellence in Research

THE UNIVERSITY
Research
Admissions
Studies
News
Cooperation and Services
About Us

CURRENT ISSUES
Research & Study
Tampere3
Vacancies

SERVICES
Administration
Career Services
Finnish Social Science Data Archive
Centre for International Education
IT services
Language Centre
Language Services
Library
Registrar's Office
Registry
Sports Activities
» more

STUDIES
Teaching schedules
Curricula guides
Student's Desktop

ONLINE SERVICES
Andor search
Renew your loans
UTA intranet
Office 365 webmail
Uta webmail
Moodle
NettiOpsu
NettiKatti
TamPub
Electronic exam service
Examination results